secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2024-11-22T23:59:59+00:00
Accession:  0001731122-24-001845
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax resolves Nasdaq delisting, appoints new director, extends NIH collaboration, posts positive Probudur results
--------------------------------------------------------------------------------

- On Nov 19, Virpax cured Nasdaq delisting notice by appointing Esha Randhawa as independent director and audit committee member.
- CEO Jatinder Dhaliwal entered contractor agreement; annual fee $200k plus milestone incentives tied to IND, trials, FDA approval.
- NIH/NCATS extended collaboration for NES100 intranasal enkephalin pain candidate, aiming for IND for acute/chronic non-cancer pain.
- Probudur minipig DRF study showed positive tolerance, no adverse effects; supports IND filing for long-acting bupivacaine formulation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000173112224001845/0001731122-24-001845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000173112224001845/e6163_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-24-001845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer